MedTrace Logo

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

NCT07023861 · Status: ENROLLING_BY_INVITATION · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-06-17

No results posted yet for this study

Summary

The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibodies in diagnosis and screening of HER2-positive cancer patients.

Conditions

Interventions

DRUG

18F-FDG

18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15 mCi/kg.

DRUG

89Zr-LNCab190

89Zr-LNCab190 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi

DRUG

89Zr-LNCab002

89Zr-LNCab002 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi

DRUG

89Zr-LNCab072

89Zr-LNCab072 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi

Sponsors & Collaborators

  • Affiliated Hospital of Jiangnan University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
15 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2026-07-07
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07023861 on ClinicalTrials.gov